FDA approves weight-loss drug Zepbound to treat sleep apnea

21 Dec 2024, 19:22 by Don Jacobson · UPI

Dec. 21 (UPI) -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.

The agency issued its decision on Friday, giving the stamp of approval for Zepbound's use among adults with obesity for use in combination with a reduced-calorie diet and increased physical activity.